Radioactive iodine-131 (RAI) therapy of metastatic well-differentiated thyroid cancer (mDTC) has been a cornerstone of nuclear medicine practice since it was first conceptualized in the 1940s by Saul Hertz and Arthur Roberts. RAI continues to be an important part of the therapeutic armamentarium for advanced thyroid cancer in both adults and children.
No takes yet. Share an insight, caveat, or question.
Bodei et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:
More from European Journal of Nuclear Medicine and Molecular Imaging